nodes	percent_of_prediction	percent_of_DWPC	metapath
Loperamide—POMC—cranial nerve—amyotrophic lateral sclerosis	0.0505	0.114	CbGeAlD
Loperamide—POMC—peripheral nervous system—amyotrophic lateral sclerosis	0.0332	0.0748	CbGeAlD
Loperamide—POMC—nerve—amyotrophic lateral sclerosis	0.0259	0.0583	CbGeAlD
Loperamide—CACNA1A—nerve—amyotrophic lateral sclerosis	0.0247	0.0557	CbGeAlD
Loperamide—POMC—hindbrain—amyotrophic lateral sclerosis	0.0194	0.0437	CbGeAlD
Loperamide—CACNA1A—hindbrain—amyotrophic lateral sclerosis	0.0185	0.0417	CbGeAlD
Loperamide—CALM1—cranial nerve—amyotrophic lateral sclerosis	0.0137	0.0309	CbGeAlD
Loperamide—CALM2—pons—amyotrophic lateral sclerosis	0.0136	0.0307	CbGeAlD
Loperamide—CALM1—pons—amyotrophic lateral sclerosis	0.0136	0.0306	CbGeAlD
Loperamide—Ileus—Riluzole—amyotrophic lateral sclerosis	0.0119	0.0974	CcSEcCtD
Loperamide—POMC—brainstem—amyotrophic lateral sclerosis	0.0111	0.025	CbGeAlD
Loperamide—CACNA1A—brainstem—amyotrophic lateral sclerosis	0.0106	0.0239	CbGeAlD
Loperamide—OPRM1—nerve—amyotrophic lateral sclerosis	0.00974	0.0219	CbGeAlD
Loperamide—CALM2—peripheral nervous system—amyotrophic lateral sclerosis	0.00907	0.0204	CbGeAlD
Loperamide—CALM1—peripheral nervous system—amyotrophic lateral sclerosis	0.00902	0.0203	CbGeAlD
Loperamide—Depressed level of consciousness—Riluzole—amyotrophic lateral sclerosis	0.00815	0.0666	CcSEcCtD
Loperamide—POMC—medulla oblongata—amyotrophic lateral sclerosis	0.00775	0.0175	CbGeAlD
Loperamide—CACNA1A—medulla oblongata—amyotrophic lateral sclerosis	0.0074	0.0167	CbGeAlD
Loperamide—CALM2—nerve—amyotrophic lateral sclerosis	0.00707	0.0159	CbGeAlD
Loperamide—CALM1—nerve—amyotrophic lateral sclerosis	0.00704	0.0159	CbGeAlD
Loperamide—POMC—spinal cord—amyotrophic lateral sclerosis	0.00691	0.0156	CbGeAlD
Loperamide—Anaphylactoid reaction—Riluzole—amyotrophic lateral sclerosis	0.00633	0.0517	CcSEcCtD
Loperamide—Urinary retention—Riluzole—amyotrophic lateral sclerosis	0.00583	0.0476	CcSEcCtD
Loperamide—POMC—nervous system—amyotrophic lateral sclerosis	0.00582	0.0131	CbGeAlD
Loperamide—POMC—central nervous system—amyotrophic lateral sclerosis	0.0056	0.0126	CbGeAlD
Loperamide—CACNA1A—nervous system—amyotrophic lateral sclerosis	0.00556	0.0125	CbGeAlD
Loperamide—POMC—cerebellum—amyotrophic lateral sclerosis	0.00548	0.0123	CbGeAlD
Loperamide—CACNA1A—central nervous system—amyotrophic lateral sclerosis	0.00535	0.0121	CbGeAlD
Loperamide—Abdominal distension—Riluzole—amyotrophic lateral sclerosis	0.00533	0.0435	CcSEcCtD
Loperamide—CALM2—hindbrain—amyotrophic lateral sclerosis	0.00529	0.0119	CbGeAlD
Loperamide—CALM1—hindbrain—amyotrophic lateral sclerosis	0.00527	0.0119	CbGeAlD
Loperamide—CACNA1A—cerebellum—amyotrophic lateral sclerosis	0.00523	0.0118	CbGeAlD
Loperamide—Haloperidol—SIGMAR1—amyotrophic lateral sclerosis	0.00447	0.604	CrCbGaD
Loperamide—POMC—brain—amyotrophic lateral sclerosis	0.00445	0.01	CbGeAlD
Loperamide—CACNA1A—brain—amyotrophic lateral sclerosis	0.00425	0.00957	CbGeAlD
Loperamide—Urinary tract disorder—Riluzole—amyotrophic lateral sclerosis	0.00419	0.0342	CcSEcCtD
Loperamide—OPRM1—brainstem—amyotrophic lateral sclerosis	0.00418	0.00942	CbGeAlD
Loperamide—Urethral disorder—Riluzole—amyotrophic lateral sclerosis	0.00416	0.0339	CcSEcCtD
Loperamide—Erythema multiforme—Riluzole—amyotrophic lateral sclerosis	0.00401	0.0327	CcSEcCtD
Loperamide—Immune system disorder—Riluzole—amyotrophic lateral sclerosis	0.00383	0.0313	CcSEcCtD
Loperamide—Flatulence—Riluzole—amyotrophic lateral sclerosis	0.00364	0.0297	CcSEcCtD
Loperamide—Angioedema—Riluzole—amyotrophic lateral sclerosis	0.00337	0.0275	CcSEcCtD
Loperamide—CALM2—embryo—amyotrophic lateral sclerosis	0.00331	0.00746	CbGeAlD
Loperamide—CALM1—embryo—amyotrophic lateral sclerosis	0.0033	0.00743	CbGeAlD
Loperamide—Loss of consciousness—Riluzole—amyotrophic lateral sclerosis	0.00324	0.0265	CcSEcCtD
Loperamide—OPRD1—nervous system—amyotrophic lateral sclerosis	0.00321	0.00724	CbGeAlD
Loperamide—Unspecified disorder of skin and subcutaneous tissue—Riluzole—amyotrophic lateral sclerosis	0.00312	0.0255	CcSEcCtD
Loperamide—Discomfort—Riluzole—amyotrophic lateral sclerosis	0.0031	0.0253	CcSEcCtD
Loperamide—OPRD1—central nervous system—amyotrophic lateral sclerosis	0.00309	0.00697	CbGeAlD
Loperamide—OPRK1—nervous system—amyotrophic lateral sclerosis	0.00308	0.00694	CbGeAlD
Loperamide—Dry mouth—Riluzole—amyotrophic lateral sclerosis	0.00307	0.0251	CcSEcCtD
Loperamide—CALM2—brainstem—amyotrophic lateral sclerosis	0.00303	0.00684	CbGeAlD
Loperamide—CALM1—brainstem—amyotrophic lateral sclerosis	0.00302	0.00681	CbGeAlD
Loperamide—Anaphylactic shock—Riluzole—amyotrophic lateral sclerosis	0.00301	0.0246	CcSEcCtD
Loperamide—OPRK1—central nervous system—amyotrophic lateral sclerosis	0.00296	0.00668	CbGeAlD
Loperamide—Nervous system disorder—Riluzole—amyotrophic lateral sclerosis	0.00295	0.0241	CcSEcCtD
Loperamide—Tamoxifen—SIGMAR1—amyotrophic lateral sclerosis	0.00294	0.396	CrCbGaD
Loperamide—Skin disorder—Riluzole—amyotrophic lateral sclerosis	0.00293	0.0239	CcSEcCtD
Loperamide—CYP2D6—hindbrain—amyotrophic lateral sclerosis	0.00292	0.00659	CbGeAlD
Loperamide—OPRK1—cerebellum—amyotrophic lateral sclerosis	0.0029	0.00653	CbGeAlD
Loperamide—CALM3—medulla oblongata—amyotrophic lateral sclerosis	0.00269	0.00607	CbGeAlD
Loperamide—Somnolence—Riluzole—amyotrophic lateral sclerosis	0.00268	0.0219	CcSEcCtD
Loperamide—Dyspepsia—Riluzole—amyotrophic lateral sclerosis	0.00265	0.0216	CcSEcCtD
Loperamide—Gastrointestinal disorder—Riluzole—amyotrophic lateral sclerosis	0.0026	0.0212	CcSEcCtD
Loperamide—OPRM1—spinal cord—amyotrophic lateral sclerosis	0.0026	0.00586	CbGeAlD
Loperamide—Fatigue—Riluzole—amyotrophic lateral sclerosis	0.0026	0.0212	CcSEcCtD
Loperamide—Constipation—Riluzole—amyotrophic lateral sclerosis	0.00258	0.021	CcSEcCtD
Loperamide—Gastrointestinal pain—Riluzole—amyotrophic lateral sclerosis	0.00246	0.0201	CcSEcCtD
Loperamide—OPRD1—brain—amyotrophic lateral sclerosis	0.00245	0.00553	CbGeAlD
Loperamide—CALM3—spinal cord—amyotrophic lateral sclerosis	0.0024	0.00541	CbGeAlD
Loperamide—Urticaria—Riluzole—amyotrophic lateral sclerosis	0.00239	0.0195	CcSEcCtD
Loperamide—Abdominal pain—Riluzole—amyotrophic lateral sclerosis	0.00238	0.0194	CcSEcCtD
Loperamide—OPRK1—brain—amyotrophic lateral sclerosis	0.00235	0.0053	CbGeAlD
Loperamide—Hypersensitivity—Riluzole—amyotrophic lateral sclerosis	0.00222	0.0181	CcSEcCtD
Loperamide—OPRM1—nervous system—amyotrophic lateral sclerosis	0.00219	0.00494	CbGeAlD
Loperamide—Asthenia—Riluzole—amyotrophic lateral sclerosis	0.00216	0.0176	CcSEcCtD
Loperamide—Pruritus—Riluzole—amyotrophic lateral sclerosis	0.00213	0.0174	CcSEcCtD
Loperamide—CALM2—medulla oblongata—amyotrophic lateral sclerosis	0.00212	0.00477	CbGeAlD
Loperamide—OPRM1—central nervous system—amyotrophic lateral sclerosis	0.00211	0.00475	CbGeAlD
Loperamide—CALM1—medulla oblongata—amyotrophic lateral sclerosis	0.00211	0.00475	CbGeAlD
Loperamide—Diarrhoea—Riluzole—amyotrophic lateral sclerosis	0.00206	0.0168	CcSEcCtD
Loperamide—Dizziness—Riluzole—amyotrophic lateral sclerosis	0.00199	0.0163	CcSEcCtD
Loperamide—Vomiting—Riluzole—amyotrophic lateral sclerosis	0.00191	0.0156	CcSEcCtD
Loperamide—CALM3—cerebellum—amyotrophic lateral sclerosis	0.0019	0.00429	CbGeAlD
Loperamide—Rash—Riluzole—amyotrophic lateral sclerosis	0.0019	0.0155	CcSEcCtD
Loperamide—Dermatitis—Riluzole—amyotrophic lateral sclerosis	0.0019	0.0155	CcSEcCtD
Loperamide—Headache—Riluzole—amyotrophic lateral sclerosis	0.00189	0.0154	CcSEcCtD
Loperamide—CALM2—spinal cord—amyotrophic lateral sclerosis	0.00189	0.00425	CbGeAlD
Loperamide—CALM1—spinal cord—amyotrophic lateral sclerosis	0.00188	0.00423	CbGeAlD
Loperamide—Nausea—Riluzole—amyotrophic lateral sclerosis	0.00179	0.0146	CcSEcCtD
Loperamide—CYP2D6—brainstem—amyotrophic lateral sclerosis	0.00168	0.00378	CbGeAlD
Loperamide—OPRM1—brain—amyotrophic lateral sclerosis	0.00167	0.00377	CbGeAlD
Loperamide—CALM2—nervous system—amyotrophic lateral sclerosis	0.00159	0.00358	CbGeAlD
Loperamide—CALM1—nervous system—amyotrophic lateral sclerosis	0.00158	0.00357	CbGeAlD
Loperamide—CALM3—brain—amyotrophic lateral sclerosis	0.00155	0.00349	CbGeAlD
Loperamide—CALM2—central nervous system—amyotrophic lateral sclerosis	0.00153	0.00345	CbGeAlD
Loperamide—CALM1—central nervous system—amyotrophic lateral sclerosis	0.00152	0.00343	CbGeAlD
Loperamide—CALM2—cerebellum—amyotrophic lateral sclerosis	0.0015	0.00337	CbGeAlD
Loperamide—CALM1—cerebellum—amyotrophic lateral sclerosis	0.00149	0.00336	CbGeAlD
Loperamide—ABCB1—embryo—amyotrophic lateral sclerosis	0.00132	0.00296	CbGeAlD
Loperamide—CALM2—brain—amyotrophic lateral sclerosis	0.00122	0.00274	CbGeAlD
Loperamide—CALM1—brain—amyotrophic lateral sclerosis	0.00121	0.00273	CbGeAlD
Loperamide—CYP2B6—nervous system—amyotrophic lateral sclerosis	0.00118	0.00266	CbGeAlD
Loperamide—CYP2B6—central nervous system—amyotrophic lateral sclerosis	0.00114	0.00256	CbGeAlD
Loperamide—CYP2C8—brain—amyotrophic lateral sclerosis	0.00101	0.00227	CbGeAlD
Loperamide—CYP2B6—brain—amyotrophic lateral sclerosis	0.000903	0.00204	CbGeAlD
Loperamide—CYP3A4—nervous system—amyotrophic lateral sclerosis	0.000892	0.00201	CbGeAlD
Loperamide—CYP2D6—nervous system—amyotrophic lateral sclerosis	0.000878	0.00198	CbGeAlD
Loperamide—CYP3A4—central nervous system—amyotrophic lateral sclerosis	0.000859	0.00194	CbGeAlD
Loperamide—CYP2D6—central nervous system—amyotrophic lateral sclerosis	0.000845	0.00191	CbGeAlD
Loperamide—ABCB1—medulla oblongata—amyotrophic lateral sclerosis	0.000841	0.00189	CbGeAlD
Loperamide—CYP2D6—cerebellum—amyotrophic lateral sclerosis	0.000826	0.00186	CbGeAlD
Loperamide—ABCB1—spinal cord—amyotrophic lateral sclerosis	0.00075	0.00169	CbGeAlD
Loperamide—CYP2D6—brain—amyotrophic lateral sclerosis	0.000671	0.00151	CbGeAlD
Loperamide—ABCB1—nervous system—amyotrophic lateral sclerosis	0.000632	0.00142	CbGeAlD
Loperamide—ABCB1—central nervous system—amyotrophic lateral sclerosis	0.000608	0.00137	CbGeAlD
Loperamide—ABCB1—cerebellum—amyotrophic lateral sclerosis	0.000594	0.00134	CbGeAlD
Loperamide—ABCB1—brain—amyotrophic lateral sclerosis	0.000483	0.00109	CbGeAlD
Loperamide—OPRK1—Signaling by GPCR—PLA2G4A—amyotrophic lateral sclerosis	0.000112	0.000262	CbGpPWpGaD
Loperamide—CACNA1A—Metabolism—PTGS2—amyotrophic lateral sclerosis	0.00011	0.000259	CbGpPWpGaD
Loperamide—ABCB1—Metabolism—DAO—amyotrophic lateral sclerosis	0.00011	0.000259	CbGpPWpGaD
Loperamide—CALM3—Metabolism—PLB1—amyotrophic lateral sclerosis	0.00011	0.000259	CbGpPWpGaD
Loperamide—CALM1—Innate Immune System—CASP9—amyotrophic lateral sclerosis	0.00011	0.000258	CbGpPWpGaD
Loperamide—CALM2—Innate Immune System—CASP9—amyotrophic lateral sclerosis	0.00011	0.000258	CbGpPWpGaD
Loperamide—CALM2—Hemostasis—SOD1—amyotrophic lateral sclerosis	0.00011	0.000257	CbGpPWpGaD
Loperamide—CALM1—Hemostasis—SOD1—amyotrophic lateral sclerosis	0.00011	0.000257	CbGpPWpGaD
Loperamide—CALM3—Adaptive Immune System—CASP9—amyotrophic lateral sclerosis	0.000109	0.000256	CbGpPWpGaD
Loperamide—OPRK1—GPCR downstream signaling—C3—amyotrophic lateral sclerosis	0.000109	0.000255	CbGpPWpGaD
Loperamide—CALM2—Metabolism—PLB1—amyotrophic lateral sclerosis	0.000107	0.00025	CbGpPWpGaD
Loperamide—CALM1—Metabolism—PLB1—amyotrophic lateral sclerosis	0.000107	0.00025	CbGpPWpGaD
Loperamide—CALM1—Adaptive Immune System—CASP9—amyotrophic lateral sclerosis	0.000106	0.000248	CbGpPWpGaD
Loperamide—CALM2—Adaptive Immune System—CASP9—amyotrophic lateral sclerosis	0.000106	0.000248	CbGpPWpGaD
Loperamide—OPRD1—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	0.000105	0.000245	CbGpPWpGaD
Loperamide—CYP2B6—Metabolism—GSR—amyotrophic lateral sclerosis	0.000105	0.000245	CbGpPWpGaD
Loperamide—CYP2D6—Metabolism—DAO—amyotrophic lateral sclerosis	0.000104	0.000244	CbGpPWpGaD
Loperamide—CALM3—Hemostasis—PLA2G4A—amyotrophic lateral sclerosis	0.000102	0.000239	CbGpPWpGaD
Loperamide—CALM3—Metabolism—GSR—amyotrophic lateral sclerosis	0.000102	0.000239	CbGpPWpGaD
Loperamide—POMC—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	9.92e-05	0.000233	CbGpPWpGaD
Loperamide—OPRK1—Signaling by GPCR—C3—amyotrophic lateral sclerosis	9.87e-05	0.000231	CbGpPWpGaD
Loperamide—CALM1—Hemostasis—PLA2G4A—amyotrophic lateral sclerosis	9.84e-05	0.000231	CbGpPWpGaD
Loperamide—CALM2—Hemostasis—PLA2G4A—amyotrophic lateral sclerosis	9.84e-05	0.000231	CbGpPWpGaD
Loperamide—CALM2—Metabolism—GSR—amyotrophic lateral sclerosis	9.84e-05	0.000231	CbGpPWpGaD
Loperamide—CALM1—Metabolism—GSR—amyotrophic lateral sclerosis	9.84e-05	0.000231	CbGpPWpGaD
Loperamide—OPRD1—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	9.81e-05	0.00023	CbGpPWpGaD
Loperamide—CALM3—Innate Immune System—ERBB4—amyotrophic lateral sclerosis	9.74e-05	0.000229	CbGpPWpGaD
Loperamide—CYP2C8—Metabolism—PLB1—amyotrophic lateral sclerosis	9.59e-05	0.000225	CbGpPWpGaD
Loperamide—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—amyotrophic lateral sclerosis	9.48e-05	0.000222	CbGpPWpGaD
Loperamide—OPRM1—Signaling by GPCR—PLA2G4A—amyotrophic lateral sclerosis	9.44e-05	0.000221	CbGpPWpGaD
Loperamide—CALM1—Innate Immune System—ERBB4—amyotrophic lateral sclerosis	9.43e-05	0.000221	CbGpPWpGaD
Loperamide—CALM2—Innate Immune System—ERBB4—amyotrophic lateral sclerosis	9.43e-05	0.000221	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—TPK1—amyotrophic lateral sclerosis	9.39e-05	0.00022	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—VAPB—amyotrophic lateral sclerosis	9.39e-05	0.00022	CbGpPWpGaD
Loperamide—POMC—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	9.37e-05	0.00022	CbGpPWpGaD
Loperamide—CALM3—Adaptive Immune System—ERBB4—amyotrophic lateral sclerosis	9.36e-05	0.000219	CbGpPWpGaD
Loperamide—OPRD1—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	9.35e-05	0.000219	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—PLB1—amyotrophic lateral sclerosis	9.22e-05	0.000216	CbGpPWpGaD
Loperamide—OPRM1—GPCR downstream signaling—C3—amyotrophic lateral sclerosis	9.18e-05	0.000215	CbGpPWpGaD
Loperamide—OPRK1—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	9.17e-05	0.000215	CbGpPWpGaD
Loperamide—CALM1—Adaptive Immune System—ERBB4—amyotrophic lateral sclerosis	9.05e-05	0.000212	CbGpPWpGaD
Loperamide—CALM2—Adaptive Immune System—ERBB4—amyotrophic lateral sclerosis	9.05e-05	0.000212	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—PLB1—amyotrophic lateral sclerosis	8.92e-05	0.000209	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—PLB1—amyotrophic lateral sclerosis	8.92e-05	0.000209	CbGpPWpGaD
Loperamide—CYP2C8—Metabolism—GSR—amyotrophic lateral sclerosis	8.85e-05	0.000208	CbGpPWpGaD
Loperamide—ABCB1—Integrated Pancreatic Cancer Pathway—CASP3—amyotrophic lateral sclerosis	8.8e-05	0.000206	CbGpPWpGaD
Loperamide—CALM3—Adaptive Immune System—CD40LG—amyotrophic lateral sclerosis	8.8e-05	0.000206	CbGpPWpGaD
Loperamide—CALM3—Platelet activation, signaling and aggregation—VEGFA—amyotrophic lateral sclerosis	8.77e-05	0.000206	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—RTN4—amyotrophic lateral sclerosis	8.67e-05	0.000203	CbGpPWpGaD
Loperamide—OPRK1—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	8.6e-05	0.000202	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—VAPA—amyotrophic lateral sclerosis	8.59e-05	0.000202	CbGpPWpGaD
Loperamide—CYP2B6—Metabolism—CHAT—amyotrophic lateral sclerosis	8.58e-05	0.000201	CbGpPWpGaD
Loperamide—CALM2—Adaptive Immune System—CD40LG—amyotrophic lateral sclerosis	8.51e-05	0.0002	CbGpPWpGaD
Loperamide—CALM1—Adaptive Immune System—CD40LG—amyotrophic lateral sclerosis	8.51e-05	0.0002	CbGpPWpGaD
Loperamide—CALM2—Platelet activation, signaling and aggregation—VEGFA—amyotrophic lateral sclerosis	8.48e-05	0.000199	CbGpPWpGaD
Loperamide—CALM1—Platelet activation, signaling and aggregation—VEGFA—amyotrophic lateral sclerosis	8.48e-05	0.000199	CbGpPWpGaD
Loperamide—CALM3—Disease—CST3—amyotrophic lateral sclerosis	8.42e-05	0.000197	CbGpPWpGaD
Loperamide—POMC—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	8.42e-05	0.000197	CbGpPWpGaD
Loperamide—CALM3—Signaling by NGF—CASP3—amyotrophic lateral sclerosis	8.41e-05	0.000197	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—RTN4—amyotrophic lateral sclerosis	8.38e-05	0.000197	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—RTN4—amyotrophic lateral sclerosis	8.38e-05	0.000197	CbGpPWpGaD
Loperamide—ABCB1—Metabolism—PLB1—amyotrophic lateral sclerosis	8.35e-05	0.000196	CbGpPWpGaD
Loperamide—CALM3—Metabolism—CHAT—amyotrophic lateral sclerosis	8.35e-05	0.000196	CbGpPWpGaD
Loperamide—OPRM1—Signaling by GPCR—C3—amyotrophic lateral sclerosis	8.34e-05	0.000196	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—VCP—amyotrophic lateral sclerosis	8.22e-05	0.000193	CbGpPWpGaD
Loperamide—OPRK1—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	8.2e-05	0.000192	CbGpPWpGaD
Loperamide—CALM1—Disease—CST3—amyotrophic lateral sclerosis	8.15e-05	0.000191	CbGpPWpGaD
Loperamide—CALM2—Disease—CST3—amyotrophic lateral sclerosis	8.15e-05	0.000191	CbGpPWpGaD
Loperamide—CALM2—Signaling by NGF—CASP3—amyotrophic lateral sclerosis	8.13e-05	0.000191	CbGpPWpGaD
Loperamide—CALM1—Signaling by NGF—CASP3—amyotrophic lateral sclerosis	8.13e-05	0.000191	CbGpPWpGaD
Loperamide—CALM3—Innate Immune System—C3—amyotrophic lateral sclerosis	8.1e-05	0.00019	CbGpPWpGaD
Loperamide—CALM2—Metabolism—CHAT—amyotrophic lateral sclerosis	8.08e-05	0.00019	CbGpPWpGaD
Loperamide—CALM1—Metabolism—CHAT—amyotrophic lateral sclerosis	8.08e-05	0.00019	CbGpPWpGaD
Loperamide—CYP2C8—Metabolism of lipids and lipoproteins—PLA2G4A—amyotrophic lateral sclerosis	8.06e-05	0.000189	CbGpPWpGaD
Loperamide—OPRD1—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	8e-05	0.000188	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—SACM1L—amyotrophic lateral sclerosis	7.99e-05	0.000187	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—PFN1—amyotrophic lateral sclerosis	7.96e-05	0.000187	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—VCP—amyotrophic lateral sclerosis	7.95e-05	0.000186	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—VCP—amyotrophic lateral sclerosis	7.95e-05	0.000186	CbGpPWpGaD
Loperamide—CYP2D6—Metabolism—PLB1—amyotrophic lateral sclerosis	7.87e-05	0.000185	CbGpPWpGaD
Loperamide—CALM1—Innate Immune System—C3—amyotrophic lateral sclerosis	7.83e-05	0.000184	CbGpPWpGaD
Loperamide—CALM2—Innate Immune System—C3—amyotrophic lateral sclerosis	7.83e-05	0.000184	CbGpPWpGaD
Loperamide—CALM3—Adaptive Immune System—C3—amyotrophic lateral sclerosis	7.78e-05	0.000182	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	7.75e-05	0.000182	CbGpPWpGaD
Loperamide—ABCB1—Metabolism—GSR—amyotrophic lateral sclerosis	7.71e-05	0.000181	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—PFN1—amyotrophic lateral sclerosis	7.7e-05	0.000181	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—PFN1—amyotrophic lateral sclerosis	7.7e-05	0.000181	CbGpPWpGaD
Loperamide—CALM1—Adaptive Immune System—C3—amyotrophic lateral sclerosis	7.52e-05	0.000176	CbGpPWpGaD
Loperamide—CALM2—Adaptive Immune System—C3—amyotrophic lateral sclerosis	7.52e-05	0.000176	CbGpPWpGaD
Loperamide—OPRD1—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	7.52e-05	0.000176	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—FIG4—amyotrophic lateral sclerosis	7.51e-05	0.000176	CbGpPWpGaD
Loperamide—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—amyotrophic lateral sclerosis	7.47e-05	0.000175	CbGpPWpGaD
Loperamide—CALM3—Immune System—SQSTM1—amyotrophic lateral sclerosis	7.42e-05	0.000174	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	7.27e-05	0.000171	CbGpPWpGaD
Loperamide—CYP2C8—Metabolism—CHAT—amyotrophic lateral sclerosis	7.27e-05	0.00017	CbGpPWpGaD
Loperamide—CYP2D6—Metabolism—GSR—amyotrophic lateral sclerosis	7.27e-05	0.00017	CbGpPWpGaD
Loperamide—CALM2—Immune System—SQSTM1—amyotrophic lateral sclerosis	7.18e-05	0.000168	CbGpPWpGaD
Loperamide—CALM1—Immune System—SQSTM1—amyotrophic lateral sclerosis	7.18e-05	0.000168	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—GFAP—amyotrophic lateral sclerosis	7.06e-05	0.000166	CbGpPWpGaD
Loperamide—OPRK1—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	7.01e-05	0.000165	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—C5AR1—amyotrophic lateral sclerosis	6.99e-05	0.000164	CbGpPWpGaD
Loperamide—CALM3—Immune System—ATF1—amyotrophic lateral sclerosis	6.96e-05	0.000163	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	6.93e-05	0.000162	CbGpPWpGaD
Loperamide—CALM3—Hemostasis—IGF1—amyotrophic lateral sclerosis	6.92e-05	0.000162	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—GFAP—amyotrophic lateral sclerosis	6.83e-05	0.00016	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—GFAP—amyotrophic lateral sclerosis	6.83e-05	0.00016	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—DAO—amyotrophic lateral sclerosis	6.79e-05	0.000159	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—C5AR1—amyotrophic lateral sclerosis	6.76e-05	0.000158	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—C5AR1—amyotrophic lateral sclerosis	6.76e-05	0.000158	CbGpPWpGaD
Loperamide—CALM1—Immune System—ATF1—amyotrophic lateral sclerosis	6.74e-05	0.000158	CbGpPWpGaD
Loperamide—CALM2—Immune System—ATF1—amyotrophic lateral sclerosis	6.74e-05	0.000158	CbGpPWpGaD
Loperamide—CALM2—Hemostasis—IGF1—amyotrophic lateral sclerosis	6.69e-05	0.000157	CbGpPWpGaD
Loperamide—CALM1—Hemostasis—IGF1—amyotrophic lateral sclerosis	6.69e-05	0.000157	CbGpPWpGaD
Loperamide—OPRD1—Signaling Pathways—C3—amyotrophic lateral sclerosis	6.65e-05	0.000156	CbGpPWpGaD
Loperamide—CYP2C8—Metabolism of lipids and lipoproteins—APOE—amyotrophic lateral sclerosis	6.63e-05	0.000156	CbGpPWpGaD
Loperamide—CALM3—Immune System—CASP9—amyotrophic lateral sclerosis	6.63e-05	0.000156	CbGpPWpGaD
Loperamide—OPRK1—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	6.59e-05	0.000155	CbGpPWpGaD
Loperamide—CALM1—Immune System—CASP9—amyotrophic lateral sclerosis	6.41e-05	0.00015	CbGpPWpGaD
Loperamide—CALM2—Immune System—CASP9—amyotrophic lateral sclerosis	6.41e-05	0.00015	CbGpPWpGaD
Loperamide—POMC—Signaling Pathways—TP53—amyotrophic lateral sclerosis	6.36e-05	0.000149	CbGpPWpGaD
Loperamide—ABCB1—Metabolism—CHAT—amyotrophic lateral sclerosis	6.33e-05	0.000148	CbGpPWpGaD
Loperamide—OPRD1—Signaling Pathways—APOE—amyotrophic lateral sclerosis	6.19e-05	0.000145	CbGpPWpGaD
Loperamide—CALM3—Disease—CASP9—amyotrophic lateral sclerosis	6.12e-05	0.000144	CbGpPWpGaD
Loperamide—CYP2D6—Metabolism—CHAT—amyotrophic lateral sclerosis	5.97e-05	0.00014	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	5.93e-05	0.000139	CbGpPWpGaD
Loperamide—CALM2—Disease—CASP9—amyotrophic lateral sclerosis	5.92e-05	0.000139	CbGpPWpGaD
Loperamide—CALM1—Disease—CASP9—amyotrophic lateral sclerosis	5.92e-05	0.000139	CbGpPWpGaD
Loperamide—CALM3—Signaling by GPCR—PLA2G4A—amyotrophic lateral sclerosis	5.84e-05	0.000137	CbGpPWpGaD
Loperamide—OPRK1—Signaling Pathways—C3—amyotrophic lateral sclerosis	5.83e-05	0.000137	CbGpPWpGaD
Loperamide—CALM3—Immune System—ERBB4—amyotrophic lateral sclerosis	5.68e-05	0.000133	CbGpPWpGaD
Loperamide—CALM2—Signaling by GPCR—PLA2G4A—amyotrophic lateral sclerosis	5.65e-05	0.000133	CbGpPWpGaD
Loperamide—CALM1—Signaling by GPCR—PLA2G4A—amyotrophic lateral sclerosis	5.65e-05	0.000133	CbGpPWpGaD
Loperamide—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—amyotrophic lateral sclerosis	5.64e-05	0.000132	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	5.57e-05	0.000131	CbGpPWpGaD
Loperamide—CALM2—Immune System—ERBB4—amyotrophic lateral sclerosis	5.49e-05	0.000129	CbGpPWpGaD
Loperamide—CALM1—Immune System—ERBB4—amyotrophic lateral sclerosis	5.49e-05	0.000129	CbGpPWpGaD
Loperamide—OPRK1—Signaling Pathways—APOE—amyotrophic lateral sclerosis	5.43e-05	0.000127	CbGpPWpGaD
Loperamide—CALM3—Immune System—CD40LG—amyotrophic lateral sclerosis	5.34e-05	0.000125	CbGpPWpGaD
Loperamide—CALM3—Disease—ERBB4—amyotrophic lateral sclerosis	5.24e-05	0.000123	CbGpPWpGaD
Loperamide—CALM2—Immune System—CD40LG—amyotrophic lateral sclerosis	5.16e-05	0.000121	CbGpPWpGaD
Loperamide—CALM1—Immune System—CD40LG—amyotrophic lateral sclerosis	5.16e-05	0.000121	CbGpPWpGaD
Loperamide—CALM3—Signaling by GPCR—C3—amyotrophic lateral sclerosis	5.16e-05	0.000121	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—PLB1—amyotrophic lateral sclerosis	5.15e-05	0.000121	CbGpPWpGaD
Loperamide—OPRD1—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	5.11e-05	0.00012	CbGpPWpGaD
Loperamide—CALM2—Disease—ERBB4—amyotrophic lateral sclerosis	5.07e-05	0.000119	CbGpPWpGaD
Loperamide—CALM1—Disease—ERBB4—amyotrophic lateral sclerosis	5.07e-05	0.000119	CbGpPWpGaD
Loperamide—CALM1—Signaling by GPCR—C3—amyotrophic lateral sclerosis	4.99e-05	0.000117	CbGpPWpGaD
Loperamide—CALM2—Signaling by GPCR—C3—amyotrophic lateral sclerosis	4.99e-05	0.000117	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—C3—amyotrophic lateral sclerosis	4.93e-05	0.000116	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	4.8e-05	0.000113	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—GSR—amyotrophic lateral sclerosis	4.75e-05	0.000111	CbGpPWpGaD
Loperamide—CALM3—Immune System—C3—amyotrophic lateral sclerosis	4.72e-05	0.000111	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	4.64e-05	0.000109	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	4.64e-05	0.000109	CbGpPWpGaD
Loperamide—CYP2B6—Metabolism—GSTP1—amyotrophic lateral sclerosis	4.61e-05	0.000108	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—APOE—amyotrophic lateral sclerosis	4.59e-05	0.000108	CbGpPWpGaD
Loperamide—CALM2—Immune System—C3—amyotrophic lateral sclerosis	4.56e-05	0.000107	CbGpPWpGaD
Loperamide—CALM1—Immune System—C3—amyotrophic lateral sclerosis	4.56e-05	0.000107	CbGpPWpGaD
Loperamide—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—amyotrophic lateral sclerosis	4.54e-05	0.000107	CbGpPWpGaD
Loperamide—CALM3—Hemostasis—VEGFA—amyotrophic lateral sclerosis	4.52e-05	0.000106	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	4.5e-05	0.000106	CbGpPWpGaD
Loperamide—CALM3—Metabolism—GSTP1—amyotrophic lateral sclerosis	4.49e-05	0.000105	CbGpPWpGaD
Loperamide—OPRK1—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	4.48e-05	0.000105	CbGpPWpGaD
Loperamide—CALM2—Hemostasis—VEGFA—amyotrophic lateral sclerosis	4.37e-05	0.000103	CbGpPWpGaD
Loperamide—CALM1—Hemostasis—VEGFA—amyotrophic lateral sclerosis	4.37e-05	0.000103	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	4.35e-05	0.000102	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	4.35e-05	0.000102	CbGpPWpGaD
Loperamide—CALM2—Metabolism—GSTP1—amyotrophic lateral sclerosis	4.34e-05	0.000102	CbGpPWpGaD
Loperamide—CALM1—Metabolism—GSTP1—amyotrophic lateral sclerosis	4.34e-05	0.000102	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	4.29e-05	0.000101	CbGpPWpGaD
Loperamide—CYP2B6—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	4.24e-05	9.94e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	4.15e-05	9.73e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	4.15e-05	9.73e-05	CbGpPWpGaD
Loperamide—CALM3—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	4.13e-05	9.68e-05	CbGpPWpGaD
Loperamide—CALM3—Disease—APOE—amyotrophic lateral sclerosis	4.05e-05	9.51e-05	CbGpPWpGaD
Loperamide—CALM2—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	3.99e-05	9.36e-05	CbGpPWpGaD
Loperamide—CALM1—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	3.99e-05	9.36e-05	CbGpPWpGaD
Loperamide—OPRD1—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	3.94e-05	9.23e-05	CbGpPWpGaD
Loperamide—CALM1—Disease—APOE—amyotrophic lateral sclerosis	3.92e-05	9.2e-05	CbGpPWpGaD
Loperamide—CALM2—Disease—APOE—amyotrophic lateral sclerosis	3.92e-05	9.2e-05	CbGpPWpGaD
Loperamide—CYP2C8—Metabolism—GSTP1—amyotrophic lateral sclerosis	3.91e-05	9.16e-05	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—CHAT—amyotrophic lateral sclerosis	3.9e-05	9.15e-05	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	3.79e-05	8.89e-05	CbGpPWpGaD
Loperamide—OPRD1—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	3.72e-05	8.72e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	3.67e-05	8.61e-05	CbGpPWpGaD
Loperamide—CYP2C8—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	3.59e-05	8.42e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	3.55e-05	8.33e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	3.55e-05	8.33e-05	CbGpPWpGaD
Loperamide—CYP2B6—Metabolism—APOE—amyotrophic lateral sclerosis	3.49e-05	8.18e-05	CbGpPWpGaD
Loperamide—OPRK1—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	3.45e-05	8.09e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	3.45e-05	8.09e-05	CbGpPWpGaD
Loperamide—CALM3—Hemostasis—TP53—amyotrophic lateral sclerosis	3.41e-05	8.01e-05	CbGpPWpGaD
Loperamide—ABCB1—Metabolism—GSTP1—amyotrophic lateral sclerosis	3.4e-05	7.98e-05	CbGpPWpGaD
Loperamide—CALM3—Metabolism—APOE—amyotrophic lateral sclerosis	3.39e-05	7.96e-05	CbGpPWpGaD
Loperamide—OPRD1—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	3.34e-05	7.83e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	3.34e-05	7.83e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	3.34e-05	7.83e-05	CbGpPWpGaD
Loperamide—CALM2—Hemostasis—TP53—amyotrophic lateral sclerosis	3.3e-05	7.75e-05	CbGpPWpGaD
Loperamide—CALM1—Hemostasis—TP53—amyotrophic lateral sclerosis	3.3e-05	7.75e-05	CbGpPWpGaD
Loperamide—CALM1—Metabolism—APOE—amyotrophic lateral sclerosis	3.28e-05	7.7e-05	CbGpPWpGaD
Loperamide—CALM2—Metabolism—APOE—amyotrophic lateral sclerosis	3.28e-05	7.7e-05	CbGpPWpGaD
Loperamide—OPRK1—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	3.26e-05	7.65e-05	CbGpPWpGaD
Loperamide—CYP2D6—Metabolism—GSTP1—amyotrophic lateral sclerosis	3.21e-05	7.52e-05	CbGpPWpGaD
Loperamide—ABCB1—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	3.13e-05	7.33e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—C3—amyotrophic lateral sclerosis	3.05e-05	7.15e-05	CbGpPWpGaD
Loperamide—CYP2C8—Metabolism—APOE—amyotrophic lateral sclerosis	2.95e-05	6.93e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—C3—amyotrophic lateral sclerosis	2.95e-05	6.92e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—C3—amyotrophic lateral sclerosis	2.95e-05	6.92e-05	CbGpPWpGaD
Loperamide—CYP2D6—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	2.95e-05	6.91e-05	CbGpPWpGaD
Loperamide—OPRK1—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	2.93e-05	6.87e-05	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	2.92e-05	6.84e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—APOE—amyotrophic lateral sclerosis	2.84e-05	6.66e-05	CbGpPWpGaD
Loperamide—CALM3—Disease—PTGS2—amyotrophic lateral sclerosis	2.78e-05	6.51e-05	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	2.76e-05	6.46e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—APOE—amyotrophic lateral sclerosis	2.75e-05	6.44e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—APOE—amyotrophic lateral sclerosis	2.75e-05	6.44e-05	CbGpPWpGaD
Loperamide—CALM1—Disease—PTGS2—amyotrophic lateral sclerosis	2.69e-05	6.3e-05	CbGpPWpGaD
Loperamide—CALM2—Disease—PTGS2—amyotrophic lateral sclerosis	2.69e-05	6.3e-05	CbGpPWpGaD
Loperamide—ABCB1—Metabolism—APOE—amyotrophic lateral sclerosis	2.57e-05	6.03e-05	CbGpPWpGaD
Loperamide—OPRD1—Signaling Pathways—TP53—amyotrophic lateral sclerosis	2.52e-05	5.92e-05	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	2.48e-05	5.8e-05	CbGpPWpGaD
Loperamide—CYP2D6—Metabolism—APOE—amyotrophic lateral sclerosis	2.42e-05	5.69e-05	CbGpPWpGaD
Loperamide—CYP2B6—Metabolism—PTGS2—amyotrophic lateral sclerosis	2.39e-05	5.61e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	2.35e-05	5.5e-05	CbGpPWpGaD
Loperamide—CALM3—Metabolism—PTGS2—amyotrophic lateral sclerosis	2.33e-05	5.46e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	2.27e-05	5.32e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	2.27e-05	5.32e-05	CbGpPWpGaD
Loperamide—CALM2—Metabolism—PTGS2—amyotrophic lateral sclerosis	2.25e-05	5.28e-05	CbGpPWpGaD
Loperamide—CALM1—Metabolism—PTGS2—amyotrophic lateral sclerosis	2.25e-05	5.28e-05	CbGpPWpGaD
Loperamide—OPRK1—Signaling Pathways—TP53—amyotrophic lateral sclerosis	2.21e-05	5.19e-05	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—GSTP1—amyotrophic lateral sclerosis	2.1e-05	4.92e-05	CbGpPWpGaD
Loperamide—CYP2C8—Metabolism—PTGS2—amyotrophic lateral sclerosis	2.02e-05	4.75e-05	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	1.93e-05	4.52e-05	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—TP53—amyotrophic lateral sclerosis	1.87e-05	4.39e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	1.81e-05	4.23e-05	CbGpPWpGaD
Loperamide—ABCB1—Metabolism—PTGS2—amyotrophic lateral sclerosis	1.76e-05	4.13e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	1.75e-05	4.1e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	1.75e-05	4.1e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	1.71e-05	4e-05	CbGpPWpGaD
Loperamide—CYP2D6—Metabolism—PTGS2—amyotrophic lateral sclerosis	1.66e-05	3.9e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	1.65e-05	3.87e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	1.65e-05	3.87e-05	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—APOE—amyotrophic lateral sclerosis	1.59e-05	3.72e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	1.53e-05	3.59e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	1.48e-05	3.48e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	1.48e-05	3.48e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—TP53—amyotrophic lateral sclerosis	1.16e-05	2.72e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—TP53—amyotrophic lateral sclerosis	1.12e-05	2.63e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—TP53—amyotrophic lateral sclerosis	1.12e-05	2.63e-05	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—PTGS2—amyotrophic lateral sclerosis	1.09e-05	2.55e-05	CbGpPWpGaD
